Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hafler, D. A.
Right arrow Articles by Weiner, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hafler, D. A.
Right arrow Articles by Weiner, H. L.
NEUROLOGY 1986;36:75
© 1986 American Academy of Neurology

Monoclonal gammopathy and neuropathy

Myelin-associated glycoprotein reactivity and clinical characteristics

David A. Hafler, MD, David Johnson, PhD, John J. Kelly, MD, Hillel Panitch, MD, Robert Kyle, MD and Howard L. Weiner, MD

Multiple Sclerosis Unit of the Center for Neurologic Diseases, Division of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (Drs. Hafler, Johnson, and Weiner); Tufts-New England Medical Center, Boston, MA (Dr. Kelly); Department of Neurology, University of Maryland School of Medicine, Baltimore, MD (Dr. Panitch); and the Division of Hematology, Mayo Clinic, Rochester, MN (Dr. Kyle).

Immunoblot analysis was performed on the serum from 29 patients with polyneuropathy and monoclonal gammopathy. Nine patients had IgM spikes, and six of the nine had reactivity against myelin-associated glycoprotein (MAG) associated with a slowly progressive, predominantly sensory neuropathy. In contrast, 23 patients who lacked anti-MAG reactivity had more severe sensory motor neuropathy. Thus, IgM monoclonal gammopathy with reactivity against MAG may define a distinct clinical entity.

Address correspondence and reprint requests to Dr. Hafler, Center for Neurologic Diseases, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115.

Supported in part by grants from the National Institutes of Health (#NS20811; D.A.H., D.J., H.L.W.) and from the Muscular Dystrophy Association (J.J.K.). Dr. Hafler is the recipient of NIH Clinical Investigator Development Award # NS00981, and is a Harry Weaver Neuroscience Scholar of the National Multiple Sclerosis Society.

Accepted for publication April 18, 1985.




This article has been cited by other articles:


Home page
 NeurologyHome page
M. I. Periquet, V. Novak, M. P. Collins, H. N. Nagaraja, S. Erdem, S. M. Nash, M. L. Freimer, Z. Sahenk, J. T. Kissel, and J. R. Mendell
Painful sensory neuropathy: Prospective evaluation using skin biopsy
Neurology, November 1, 1999; 53(8): 1641 - 1641.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
D. Adams and G. Said
Ultrastructural characterisation of the M protein in nerve biopsy of patients with POEMS syndrome
J. Neurol. Neurosurg. Psychiatry, June 1, 1998; 64(6): 809 - 812.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
J. J. Kelly, L. S. Adelman, E. Berkman, and I. Bhan
Polyneuropathies Associated With IgM Monoclonal Gammopathies
Arch Neurol, December 1, 1988; 45(12): 1355 - 1359.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by AAN Enterprises, Inc.